Theranexus
Theranexus is a French clinical-stage biopharmaceutical company (THX Pharma) that designs antisense oligonucleotide drug candidates for rare neurological diseases, with four candidates in development targeting five indications including CLN3 Batten, Niemann-Pick C, and Gaucher.
- Company typePublic
- Founded2013
- HeadquartersOrsay, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Theranexus does
Theranexus (trading as THX Pharma) is a French clinical-stage biopharmaceutical company founded in 2013 as a spin-off of the CEA (Commissariat à l'énergie atomique et aux énergies alternatives), headquartered in Fontenay-aux-Roses in the Paris metropolitan area. The company is publicly listed on Euronext Growth Paris under ticker ALTHX and operates with a small team of 11–50 employees.
Theranexus focuses exclusively on rare neurological diseases where therapeutic options remain limited. Its research department employs an antisense oligonucleotide (ASO) platform — an agile, evolving technological foundation that designs drug candidates capable of precisely targeting disease mechanisms. The current disclosed pipeline comprises four drug candidates targeting five rare diseases, with three named lead programs: an ASO candidate for juvenile Batten disease (CLN3 form), an ASO candidate for Niemann-Pick type C disease, and an ASO candidate for Gaucher disease. The company protects this portfolio with three patent families covering the platform and individual candidates.
Theranexus has no commercialized products and consequently no material product revenue at present. Its stated revenue model is licensing and royalties, with the company positioned to monetize candidates through co-development partnerships, licensing agreements, and eventually commercialization — likely via specialty and hospital pharmacy channels and partnerships with larger pharmaceutical companies. GTM motion is sales-led and oriented toward out-licensing or partnership with major pharma for late-stage development and global reach. A core institutional partnership with CEA underpins the company's access to scientific infrastructure and innovation pipeline.
Theranexus firmographics
Firmographics- Name
- Theranexus
- Legal name
- Theranexus
- Website
- https://theranexus.com
- Company type
- Public
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Theranexus is a French clinical-stage biopharmaceutical company (THX Pharma) that designs antisense oligonucleotide drug candidates for rare neurological diseases, with four candidates in development targeting five indications including CLN3 Batten, Niemann-Pick C, and Gaucher.
- Ownership category
- akta.pro rank
Theranexus industry classification
Industry- Product category
- Rare Disease Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH)
Keywords
Where Theranexus is headquartered
LocationHeadquarters
- HQ city
- Orsay
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Theranexus business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Drug Development and Licensing: As a biopharmaceutical company in the development stage with 4 drug candidates in its pipeline, Theranexus generates revenue through potential licensing agreements, co-development partnerships, and eventual commercialization of its therapeutic candidates for rare neurological diseases.
Go-to-market motion1 record
Marketing channels1 record
Theranexus product offering
Product offeringCore offering
Theranexus (THX Pharma) is a clinical-stage biopharmaceutical company developing antisense oligonucleotide-based drug candidates for rare neurological diseases. The company has 4 drug candidates in its pipeline targeting 5 diseases, with named programs for juvenile Batten disease (CLN3 form), Niemann-Pick type C disease, and Gaucher disease. The company is pre-commercial and intends to monetize its pipeline through licensing, co-development partnerships, and eventual commercialization of therapeutic candidates.
Product overview
THX Pharma (Theranexus) is a biopharmaceutical company developing antisense oligonucleotide-based drug candidates for rare neurological diseases. The company has 4 drug candidates in development targeting 5 diseases, including programs for Batten disease (CLN3), Niemann-Pick C disease, and Gaucher disease. Founded in 2013 and spun out from CEA, the company leverages an agile technological platform to design drug candidates that precisely target disease mechanisms and transform scientific innovation into concrete advances for patients.
Differentiator
Problem solved
Functional benefit
Products and services
- Drug Candidate for Batten Disease (CLN3)
- Drug Candidate for Niemann-Pick C Disease
- Drug Candidate for Gaucher Disease Antisense oligonucleotide drug candidate for Gaucher disease, a rare genetic disease with multiple manifestations and variable progression, addressing the importance of developing new therapeutic approaches tailored to patient needs.
Quantifiable outcome
- 4 drug candidates in clinical development pipeline targeting 5 rare neurological diseases
Companies that use Theranexus
Customer profileSegments3 records
Ideal customer profiles2 records
Theranexus technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Theranexus partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CEA (French Alternative Energies and Atomic Energy Commission)coreTheranexus originated from CEA (Commissariat à l'énergie atomique et aux énergies alternatives), the French Alternative Energies and Atomic Energy Commission. This institutional partnership provides access to scientific expertise, research infrastructure, and a pipeline of innovations for the company.
Scale indicators4 records
Recent moves5 records
Expansion highlights4 records
Theranexus competitors and assessment
Company assessmentOthers
Emerging players
- Orphazyme: Historical developer of therapies for Niemann-Pick C and other rare neurological diseases. Comparable focus on the same indication despite differing modalities.
- Stoke Therapeutics: Clinical-stage company developing antisense oligonucleotide-based therapies for severe genetic diseases including CNS indications. Comparable as a smaller oligonucleotide-focused peer targeting rare diseases.
- Cycle Therapeutics (Cyclo): Clinical-stage company developing treatments for Niemann-Pick Type C disease. Direct overlap with one of Theranexus's primary pipeline indications.
Broad incumbents
- Pfizer: Large biopharma with significant rare disease portfolio and active oligonucleotide / gene therapy programs. Potential licensing partner and broad competitor for rare disease assets.
- Alnylam Pharmaceuticals: Established leader in RNA-targeted therapeutics with broad oligonucleotide platform. Comparable in modality and rare disease focus, but operates at much greater scale and commercial maturity.
Direct peers
- Wave Life Sciences: Clinical-stage company developing stereopure antisense oligonucleotides for rare neurological diseases including Huntington's. Closely comparable modality and indication focus.
- Ionis Pharmaceuticals: Pioneer of antisense oligonucleotide therapeutics with a broad pipeline including CNS and rare disease programs. Directly comparable as an antisense platform developer targeting neurological indications.
- Sarepta Therapeutics: Leader in RNA-targeted therapeutics for rare neurological and neuromuscular diseases. Highly comparable given shared antisense/RNA modality and rare disease focus.
- BioMarin Pharmaceutical: Specialty rare disease biopharma with active programs in Niemann-Pick C and other genetic conditions. Direct competitor for Theranexus's Niemann-Pick C candidate.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
Theranexus social profiles
Digital presenceTheranexus financial estimates
Financial estimateRevenue estimate
Valuation estimate
Theranexus leadership team
Management profileNumber of profiles
Profiles4 records
Theranexus funding detail
Funding detailFunding overview
Funding rounds2 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Theranexus M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Theranexus
What does Theranexus do?
Theranexus (THX Pharma) is a clinical-stage biopharmaceutical company developing antisense oligonucleotide-based drug candidates for rare neurological diseases. The company has 4 drug candidates in its pipeline targeting 5 diseases, with named programs for juvenile Batten disease (CLN3 form), Niemann-Pick type C disease, and Gaucher disease. The company is pre-commercial and intends to monetize its pipeline through licensing, co-development partnerships, and eventual commercialization of therapeutic candidates.
Is Theranexus a public or private company?
Theranexus is a public company. It is classified as public and is currently operating.
When was Theranexus founded?
Theranexus was founded in 2013. It employs 11 to 50 people.
Where is Theranexus based?
Theranexus is headquartered in Orsay, France, in the Europe region.
How does Theranexus make money?
One revenue line is on record: drug Development and Licensing.
Who are Theranexus's main competitors?
Roche is listed as an others. Emerging players are Orphazyme, Stoke Therapeutics and Cycle Therapeutics (Cyclo). Broad incumbents are Pfizer and Alnylam Pharmaceuticals. Direct peers are Wave Life Sciences, Ionis Pharmaceuticals, Sarepta Therapeutics and BioMarin Pharmaceutical.
Does Theranexus have an API?
No public API is recorded for Theranexus.
What industry is Theranexus in?
Theranexus's product category is Rare Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAH, Rare Cardiovascular & Vascular Disorder Therapies. Its NAICS code is 325414 and its SIC code is 2836.